The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer

British Journal of Urology

Volumn 81, Issue 6, 1998, Pages 834-838

  Kochanska Dziurowicz A A ^a   Mielniczuk, M R ^b   Stojko, A ^c   Kaletka, J ^a  

^a INSTITUTE OF OCCUPATIONAL MEDICINE AND ENVIRONMENTAL HEALTH   (Poland)

^b Department of Urology

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Benign prostatic hyperplasia; Free to total prostate specific antigen ratio; Prostate cancer; PSA density

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

AGED; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0031864036     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00643.x     Document Type: Article

References (22)

1. Papsidero LD, Wang MC, Valenzuela LA, Murphy GT. Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980: 40: 2428-32
2. Stamey TA, Yang N. Hay AR, McNeal JE, Freiha FS. Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16
3. Kuriyama M, Wang MC, Lee C-I et al. Use of human prostate-specific antigen in monitoring prostate cancer patients. Cancer Res 1981; 41: 3874-6
4. Oesterling JE. Chan DW. Epstein JL et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988: 39: 766-72
5. Papsidero LD, Kuriyama M, Wang MC et al. Prostate antigen: A marker for human prostate epithelial cells. J Nat Cancer Inst 1981; 48: 1229-32
6. Benson MC. Whang IS. Pantuck A et al. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-6
7. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54
8. Catalona WJ, Richie JP, Ahmann FR et al Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 1994: 151: 1283-90
9. Kochanska-Dziurowicz A, Mielniczuk M, Szewczyk W, Kasperkiewicz K. Usefulness of measurement concentration of serum free and total prostatic specific antigen, between 4.0 and 10.0 ng/mL. in differentiation prostate cancer and benign prostatic hyperplasia (Polish). Pol J Urol 1998: in press
10. WolffJW. Scholz A, Boeckmann W. Jakse G. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density. Eur Urol 1994; 25: 295-8
11. Benson MC. Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-21
12. Lilja H. Christensson A, Dahlen U et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha- 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
13. Watt K, Lee PJ. M.'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: Structural et functional similarity with serine proteases. Proc Nat! Acad Sei USA 1986; 83: 3166-70
14. Becker C. Lilja H. Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Clin Chim Acta 1997; 257: 117-32
15. Stenman UH. Leinonen J. Alfthan H, Ranniko S. Tuhkanen K. Alfthan 0. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostatespecific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991: 51: 222-6
16. Christensson A. Bjork T. Nilsson 0 et al. Serum prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
17. Hanley JA, McNeil BJ. The meaning and use of the area under receiver operating characteristic (ROC) curve. Radiology 1982: 143: 29-36
18. Hanley JA. McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43
19. Catalona WJ, Richie JP, deKernion JB et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994: 152: 2031-6
20. Prestigiacomo AF. Stamey TA. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 1997: 157: 189-94
21. Van Cangh PJ, De Nayer P, Sauvage P et al. Free to total prostate-specific antigen (PSA) ratio superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl 1996; 7: 30-4
22. Morgan TO. McLeod DG. Leifer ES. Moul JW. Murphy GP. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl 1996; 7: 58-63